<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00322868</url>
  </required_header>
  <id_info>
    <org_study_id>CFFTI-Pio001</org_study_id>
    <nct_id>NCT00322868</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Pioglitazone as an Anti-inflammatory for the Treatment of Cystic Fibrosis (CF) Lung Disease</brief_title>
  <official_title>A Pilot Study Assessing the Safety and Efficacy of Pioglitazone as an Anti-inflammatory Agent for the Treatment of CF Lung Disease in Patients With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation Therapeutics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Hypothesis: Pioglitazone may decrease inflammation in cystic fibrosis lung disease.

      Primary outcomes: Markers of inflammation (neutrophils, elastase, cytokines and bacteria)will
      be measured in induced sputum specimens before and after a 4 week treatment period with
      pioglitazone in clinically stable CF patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Single-center, open label study of pioglitazone in clinically stable patients with mild
           to moderate CF lung disease

        -  Induced sputum will be obtained from each subject at enrollment (Baseline) and again
           following 28 days of pioglitazone treatment (End of Treatment)

        -  Changes in markers of inflammation in the sputum samples will be assessed

        -  Safety measures, including complete blood count (CBC), serum chemistry, Erythrocyte
           sedimentation rate (ESR), C-Reactive Protein (CRP), urinalysis and spirometry, will also
           be assessed
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This was open-label and no one was masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Sputum White Cell Count</measure>
    <time_frame>Day 0 and Day 29</time_frame>
    <description>The total number of white cells log 10 cells/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sputum Neutrophil Count</measure>
    <time_frame>Day 0 and Day 29</time_frame>
    <description>sputum neutrophils log 10 (cells/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sputum Neutrophil Percent</measure>
    <time_frame>Day 0 and Day 29</time_frame>
    <description>Neutrophils as a percent of the total white cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sputum Active Elastase</measure>
    <time_frame>Day 0 and Day 29</time_frame>
    <description>Log 10 of Concentration of active Elastase in mcg/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sputum TNFα</measure>
    <time_frame>Day 0 and Day 29</time_frame>
    <description>The concentration of Tumor Necrosis Factor-α (TNFα) log 10 (pg/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sputum IL-1ß</measure>
    <time_frame>Day 0 and Day 29</time_frame>
    <description>The concentration of Interleukin-1ß (IL-1ß) log 10 (pg/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sputum IL-6</measure>
    <time_frame>Day 0 and Day 29</time_frame>
    <description>The concentration of Interleukin-6 (IL-6) log 10 (pg/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sputum IL-8</measure>
    <time_frame>Day 0 and Day 29</time_frame>
    <description>Concentration of Interleukin-8 log 10 (pg/mL)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects treated for 28 days with pioglitazone, 30 mg orally, once daily Other names: Actos, Takeda</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone</intervention_name>
    <description>All subjects treated for 28 days with pioglitazone, 30 mg orally, once daily.</description>
    <arm_group_label>Pioglitazone</arm_group_label>
    <other_name>Actos</other_name>
    <other_name>Takeda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female &gt;= 28 years of age

          -  Confirmed diagnosis of cystic fibrosis

          -  Forced Expiratory Volume in 1 second (FEV1) &gt;= 40% predicted

          -  Clinically stable

          -  Ability to reproduce spirometry

          -  Ability to understand and sign the informed consent

        Exclusion Criteria:

          -  Use of an investigational agent within 4-week period prior to Visit 1

          -  Chronic daily use of ibuprofen or other NSAIDS

          -  Chronic daily use of insulin,oral diabetic agents or oral hypoglycemic agents

          -  History of hypersensitivity to beta agonists

          -  History of hypersensitivity to glitazones

          -  Oxygen saturation&lt;92%

          -  Pregnant, breastfeeding or unwilling to practice acceptable birth control

          -  History of hemoptysis &gt;30cc per episode within 30 days prior to Visit 1

          -  Significant history of hepatic, cardiovascular, renal,neurologic, hematologic or
             peptic ulcer disease

          -  Serum Glutamic-Oxaloacetic Transaminase (SGOT)/(Serum Glutamic Pyruvic Transaminase
             (SGPT) &gt;3 times the upper limit of normal at screening, documented biliary
             cirrhosis,or portal hypertension

          -  Creatinine &gt; 1.8 mg/dL at screening

          -  Inability to swallow pills

          -  Presence or abnormality that in the opinion of the investigator would compromise the
             safety or the quality of the data

          -  Subjects who have routinely taken ibuprofen or other NSAIDS; prednisone or other
             systemic corticosteroids, or insulin, or oral diabetic agents within 4 weeks prior to
             visit 1 or who have taken these medications as needed within 72 hours prior to visit
             one will be excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael W. Konstan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case University and Rainbow Babies and Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2006</study_first_submitted>
  <study_first_submitted_qc>May 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2006</study_first_posted>
  <results_first_submitted>December 3, 2016</results_first_submitted>
  <results_first_submitted_qc>February 21, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 23, 2018</results_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals Cleveland Medical Center</investigator_affiliation>
    <investigator_full_name>Michael W. Konstan</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Prescription drugs</keyword>
  <keyword>Administration, oral</keyword>
  <keyword>Durable medical equipment</keyword>
  <keyword>Kinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individualized personal data (IPD) will not be shared</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All patients who will be approached for participation in this trial will first be identified using either Port CF (CFF Registry) or CF Center database. Once potentials are identified a chart review will be conducted to determine eligibility. Patients will approached at clinic for possible participation in the study.</recruitment_details>
      <pre_assignment_details>Washout: A 4 week washout from chronic use of NSAIDs, corticosteroids and oral meds to treat diabetes will be required. Subjects will be excluded if they take these medication within 72 hours of Visit 1. Subjects using alternate month tobramycin for inhalation (TOBI) will need to be on an off cycle to participate in this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pioglitazone (30 mg)</title>
          <description>After screening eligibility requirements were met, cystic fibrosis subjects received pioglitazone orally, 30 mg, once daily, for 28 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>disease progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>21 subjects were screened and enrolled with 1 subject withdrawal due to disease progression.</population>
      <group_list>
        <group group_id="B1">
          <title>Pioglitazone (30 mg)</title>
          <description>After screening eligibility requirements were met, cystic fibrosis subjects received pioglitazone orally, 30 mg, once daily, for 28 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>great or equal to 18 years of age</description>
          <population>1 subject withdrawn due to disease progression</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" spread="9.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>1 subject was withdrawn and no samples analyzed</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>1 subject withdrawn due to disease progression. no samples analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>1 subject withdrawn due to disease progression no samples analyzed</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>1 subject was withdrawn due to disease progression. No samples analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total white cell count</title>
          <population>1 subject withdrawn due to disease progression. No samples analyzed.</population>
          <units>log 10 (cells/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.93" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total neutrophil count</title>
          <population>1 subject withdrawn due to disease progression. No samples analyzed.</population>
          <units>Log 10 (PMN/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.88" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>percent neutrophils</title>
          <population>1 subject withdrawn due to disease progression. No samples analyzed</population>
          <units>percent of white blood cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.47" spread="11.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sputum White Cell Count</title>
        <description>The total number of white cells log 10 cells/mL</description>
        <time_frame>Day 0 and Day 29</time_frame>
        <population>Of the 20 enrolled subjects, one did not produce sputum at Baseline and a second subject's Post-Treatment sputum sample was lost due to a lab error. This reduced the number of subjects per group to 19. Of these 19 subjects, 18 subjects had both Baseline and Post-Treatment sputum samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Results pre-Pioglitazone dosing</description>
          </group>
          <group group_id="O2">
            <title>Post-Treatment</title>
            <description>Results following 28 days of Pioglitazone (oral, 30mg, once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum White Cell Count</title>
          <description>The total number of white cells log 10 cells/mL</description>
          <population>Of the 20 enrolled subjects, one did not produce sputum at Baseline and a second subject's Post-Treatment sputum sample was lost due to a lab error. This reduced the number of subjects per group to 19. Of these 19 subjects, 18 subjects had both Baseline and Post-Treatment sputum samples.</population>
          <units>log 10 (cells/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.93" spread="0.40"/>
                    <measurement group_id="O2" value="6.81" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2772</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>Paired t-test analysis of the intra-subject change in log10 sputum white cell count</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sputum Neutrophil Count</title>
        <description>sputum neutrophils log 10 (cells/mL)</description>
        <time_frame>Day 0 and Day 29</time_frame>
        <population>Of the 20 enrolled subjects, one did not produce sputum at Baseline and a second subject's Post-Treatment sputum sample was lost due to a lab error. This reduced the number of subjects per group to 19. Of these 19 subjects, 18 subjects had both Baseline and Post-Treatment sputum samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Results pre-Pioglitazone dosing</description>
          </group>
          <group group_id="O2">
            <title>Post-Treatment</title>
            <description>Results following 28 days of Pioglitazone (oral, 30mg, once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Neutrophil Count</title>
          <description>sputum neutrophils log 10 (cells/mL)</description>
          <population>Of the 20 enrolled subjects, one did not produce sputum at Baseline and a second subject's Post-Treatment sputum sample was lost due to a lab error. This reduced the number of subjects per group to 19. Of these 19 subjects, 18 subjects had both Baseline and Post-Treatment sputum samples.</population>
          <units>log 10 (cells/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.88" spread="0.39"/>
                    <measurement group_id="O2" value="6.75" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2467</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>Paired t-test analysis of the intra-subject change in log10 sputum neutrophil count</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sputum Neutrophil Percent</title>
        <description>Neutrophils as a percent of the total white cells.</description>
        <time_frame>Day 0 and Day 29</time_frame>
        <population>Of the 20 enrolled subjects, one did not produce sputum at Baseline and a second subject's Post-Treatment sputum sample was lost due to a lab error. This reduced the number of subjects per group to 19. Of these 19 subjects, 18 subjects had both Baseline and Post-Treatment sputum samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Results pre-Pioglitazone dosing</description>
          </group>
          <group group_id="O2">
            <title>Post-Treatment</title>
            <description>Results following 28 days of Pioglitazone (oral, 30mg, once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Neutrophil Percent</title>
          <description>Neutrophils as a percent of the total white cells.</description>
          <population>Of the 20 enrolled subjects, one did not produce sputum at Baseline and a second subject's Post-Treatment sputum sample was lost due to a lab error. This reduced the number of subjects per group to 19. Of these 19 subjects, 18 subjects had both Baseline and Post-Treatment sputum samples.</population>
          <units>Percent (%) of white blood cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.47" spread="11.88"/>
                    <measurement group_id="O2" value="74.44" spread="17.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0288</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>Paired t-test analysis of the intra-subject change in sputum percent neutrophils</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sputum Active Elastase</title>
        <description>Log 10 of Concentration of active Elastase in mcg/mL</description>
        <time_frame>Day 0 and Day 29</time_frame>
        <population>Of the 20 enrolled subjects, one did not produce sputum at Baseline and a second subject's Post-Treatment sputum sample was lost due to a lab error. This reduced the number of subjects per group to 19. Of these 19 subjects, 18 subjects had both Baseline and Post-Treatment sputum samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Results pre-Pioglitazone dosing</description>
          </group>
          <group group_id="O2">
            <title>Post-Treatment</title>
            <description>Results following 28 days of Pioglitazone (oral, 30mg, once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Active Elastase</title>
          <description>Log 10 of Concentration of active Elastase in mcg/mL</description>
          <population>Of the 20 enrolled subjects, one did not produce sputum at Baseline and a second subject's Post-Treatment sputum sample was lost due to a lab error. This reduced the number of subjects per group to 19. Of these 19 subjects, 18 subjects had both Baseline and Post-Treatment sputum samples.</population>
          <units>log 10 (mcg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" spread="0.36"/>
                    <measurement group_id="O2" value="1.96" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.50</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>Paired t-test analysis of the intra-subject change in log10 sputum active elastase</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sputum TNFα</title>
        <description>The concentration of Tumor Necrosis Factor-α (TNFα) log 10 (pg/mL)</description>
        <time_frame>Day 0 and Day 29</time_frame>
        <population>Of the 20 enrolled subjects, one did not produce sputum at Baseline and a second subject's Post-Treatment sputum sample was lost due to a lab error. This reduced the number of subjects per group to 19. Of these 19 subjects, 18 subjects had both Baseline and Post-Treatment sputum samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Results pre-Pioglitazone dosing</description>
          </group>
          <group group_id="O2">
            <title>Post-Treatment</title>
            <description>Results following 28 days of Pioglitazone (oral, 30mg, once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum TNFα</title>
          <description>The concentration of Tumor Necrosis Factor-α (TNFα) log 10 (pg/mL)</description>
          <population>Of the 20 enrolled subjects, one did not produce sputum at Baseline and a second subject's Post-Treatment sputum sample was lost due to a lab error. This reduced the number of subjects per group to 19. Of these 19 subjects, 18 subjects had both Baseline and Post-Treatment sputum samples.</population>
          <units>log 10 (pg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="0.49"/>
                    <measurement group_id="O2" value="1.69" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>Paired t-test analysis of the intra-subject change in log10 sputum TNFα</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sputum IL-1ß</title>
        <description>The concentration of Interleukin-1ß (IL-1ß) log 10 (pg/mL)</description>
        <time_frame>Day 0 and Day 29</time_frame>
        <population>Of the 20 enrolled subjects, one did not produce sputum at Baseline and a second subject's Post-Treatment sputum sample was lost due to a lab error. This reduced the number of subjects per group to 19. Of these 19 subjects, 18 subjects had both Baseline and Post-Treatment sputum samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Results pre-Pioglitazone dosing</description>
          </group>
          <group group_id="O2">
            <title>Post-Treatment</title>
            <description>Results following 28 days of Pioglitazone (oral, 30mg, once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum IL-1ß</title>
          <description>The concentration of Interleukin-1ß (IL-1ß) log 10 (pg/mL)</description>
          <population>Of the 20 enrolled subjects, one did not produce sputum at Baseline and a second subject's Post-Treatment sputum sample was lost due to a lab error. This reduced the number of subjects per group to 19. Of these 19 subjects, 18 subjects had both Baseline and Post-Treatment sputum samples.</population>
          <units>log 10 (pg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.05" spread="0.42"/>
                    <measurement group_id="O2" value="3.99" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.50</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>Paired t-test analysis of the intra-subject change in log10 sputum IL-1ß</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sputum IL-6</title>
        <description>The concentration of Interleukin-6 (IL-6) log 10 (pg/mL)</description>
        <time_frame>Day 0 and Day 29</time_frame>
        <population>Of the 20 enrolled subjects, one did not produce sputum at Baseline and a second subject's Post-Treatment sputum sample was lost due to a lab error. This reduced the number of subjects per group to 19. Of these 19 subjects, 18 subjects had both Baseline and Post-Treatment sputum samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Results pre-Pioglitazone dosing</description>
          </group>
          <group group_id="O2">
            <title>Post-Treatment</title>
            <description>Results following 28 days of Pioglitazone (oral, 30mg, once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum IL-6</title>
          <description>The concentration of Interleukin-6 (IL-6) log 10 (pg/mL)</description>
          <population>Of the 20 enrolled subjects, one did not produce sputum at Baseline and a second subject's Post-Treatment sputum sample was lost due to a lab error. This reduced the number of subjects per group to 19. Of these 19 subjects, 18 subjects had both Baseline and Post-Treatment sputum samples.</population>
          <units>log 10 (pg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="0.33"/>
                    <measurement group_id="O2" value="1.41" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>Paired t-test analysis of the intra-subject change in log10 sputum IL-6</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sputum IL-8</title>
        <description>Concentration of Interleukin-8 log 10 (pg/mL)</description>
        <time_frame>Day 0 and Day 29</time_frame>
        <population>Of the 20 enrolled subjects, one did not produce sputum at Baseline and a second subject's Post-Treatment sputum sample was lost due to a lab error. This reduced the number of subjects per group to 19. Of these 19 subjects, 18 subjects had both Baseline and Post-Treatment sputum samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Results pre-Pioglitazone dosing</description>
          </group>
          <group group_id="O2">
            <title>Post-Treatment</title>
            <description>Results following 28 days of Pioglitazone (oral, 30mg, once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum IL-8</title>
          <description>Concentration of Interleukin-8 log 10 (pg/mL)</description>
          <population>Of the 20 enrolled subjects, one did not produce sputum at Baseline and a second subject's Post-Treatment sputum sample was lost due to a lab error. This reduced the number of subjects per group to 19. Of these 19 subjects, 18 subjects had both Baseline and Post-Treatment sputum samples.</population>
          <units>log 10 (pg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.13" spread="0.35"/>
                    <measurement group_id="O2" value="5.10" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.75</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>Paired t-test analysis of the intra-subject change in log10 sputum IL-8</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pioglitazone (30 mg)</title>
          <description>After screening eligibility requirements were met, cystic fibrosis subjects received pioglitazone orally,30 mg, once daily for 28 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hypoglycemic event</sub_title>
                <description>Non serious, unexpected, possibly study related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael W Konstan, MD</name_or_title>
      <organization>Case Western Reserve University</organization>
      <phone>2168443267</phone>
      <email>michael.konstan@case.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

